Virtus LifeSci Biotech Clinical Trials ETF (BBC)
- Previous Close
25.38 - Open
25.67 - Bid 25.64 x 1000
- Ask 25.70 x 800
- Day's Range
25.63 - 25.63 - 52 Week Range
16.88 - 31.99 - Volume
229 - Avg. Volume
4,245 - Net Assets 11.66M
- NAV 25.22
- PE Ratio (TTM) --
- Yield 0.28%
- YTD Daily Total Return 2.95%
- Beta (5Y Monthly) 0.93
- Expense Ratio (net) 0.79%
Under normal market conditions, the fund will invest not less than 80% of its assets in component securities of the index. The index seeks to track the performance of the common stock of U.S. exchange-listed biotechnology companies with a primary product offering ("lead drug") that is typically in a Phase 1, Phase 2 or Phase 3 clinical trial stage of development, but prior to receiving marketing approval.
Virtus
Fund Family
Health
Fund Category
11.66M
Net Assets
2014-12-16
Inception Date
Performance Overview: BBC
Trailing returns as of 4/22/2024. Category is Health.
People Also Watch
Holdings: BBC
Top 10 Holdings (19.93% of Total Assets)
Sector Weightings
Related ETF News
Research Reports: BBC
Analyst Report: Netflix Inc
Netflix is a video-on-demand distributor of movies and television shows over the internet worldwide (except China and a few other countries). Subscribers have access to the Netflix content library for a fixed monthly subscription fee. The company offers several service tiers, including a discount advertising-supported service. Netflix derives 59% of its revenue from outside the U.S.
RatingPrice TargetMarket Digest: PLD, CSX, FITB, NFLX, UNH
Monday Tee Up: Here Comes Big Tech
Analyst Report: Netflix, Inc.
Netflix’s relatively simple business model involves only one business, its streaming service. It has the biggest television entertainment subscriber base in both the United States and the collective international market, with almost 250 million subscribers globally. Netflix has exposure to nearly the entire global population outside of China. The firm has traditionally avoided live programming or sports content, instead focusing on on-demand access to episodic television, movies, and documentaries. The firm recently began introducing ad-supported subscription plans, giving the firm exposure to the advertising market in addition to the subscription fees that have historically accounted for nearly all its revenue.
RatingPrice TargetVRSN: Raising target price to $201.00
VERISIGN INC has an Investment Rating of HOLD; a target price of $201.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of Medium; and a Value Subrating of Medium.
RatingPrice Target